AMGEN INC

AMGN Healthcare & Pharma 5/10 Medium Risk
5/10

AMGEN INC has $60.1B in total long-term debt with $56.0B in scheduled maturities. Approximately $4.6B (8% of maturities) is due within the next twelve months. Overall, AMGN carries moderate refinancing risk (score 5/10).

Maturity Schedule

Year 1 $4.6B Year 2 $2.7B Year 3 $5.0B Year 4 $2.9B Year 5 $4.0B Beyond 5 $36.8B
Period Amount Due % of Total
Year 1 (0-12 months) $4.6B 8.2%
Year 2 (12-24 months) $2.7B 4.9%
Year 3 (24-36 months) $5.0B 8.9%
Year 4 (36-48 months) $2.9B 5.3%
Year 5 (48-60 months) $4.0B 7.1%
Beyond 5 Years $36.8B 65.7%
Total Scheduled Maturities $56.0B 100.0%

Key Metrics

Total Long-Term Debt
$60.1B
Near-Term (12mo)
$4.6B
Interest Coverage
N/A
Debt/Equity
16.42
Cash Coverage
2.62x
Operating Income
$7.9B

Score Components

Component Value Weight
Near-Term Maturity Concentration 8.2% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 16.42 25%
Cash Coverage of Near-Term Debt 2.62x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B
REGENERON PHARMACEUTICALS, INC.
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-13. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.